Streetbeat News

Earnings

AXP

IPAY

JRNY

American Express Co (AXP) reported a first-quarter revenue increase of 11% year-on-year to $15.80 billion, slightly above consensus estimates. The growth was driven by higher net interest income and increased Card Member spending. EPS was $3.33, surpassing the consensus of $2.95. The company also reiterated its FY24 revenue growth outlook of 9%-11%. Despite mixed analyst opinions regarding credit quality and growth, AXP's stock has gained 32% over the last 12 months. AXP's performance can impact related ETFs like IPAY and JRNY.

Portfolio Pulse from Anusuya Lahiri

April 19, 2024 | 12:30 pm

BDRX

Biodexa Pharmaceuticals reported a preliminary FY23 earnings per share (EPS) of £(0.02), indicating a loss for the fiscal year.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 12:14 pm

ISRG

Intuitive Surgical Inc (NASDAQ:ISRG) reported Q1 revenue of $1.89 billion, surpassing the consensus estimate of $1.87 billion, and adjusted earnings of $1.50 per share, beating estimates of $1.41 per share. Revenue was up 11% year-over-year, and the installed base of da Vinci surgical systems grew by 14%. Despite the positive results, shares fell 0.4% to close at $372.63. Analysts from Baird and Jefferies revised their price targets for ISRG following the earnings announcement, with Baird reducing its target from $440 to $436 while maintaining an Outperform rating, and Jefferies raising its target from $365 to $375 with a Hold rating.

Portfolio Pulse from Avi Kapoor

April 19, 2024 | 12:10 pm

MTN

Vail Resorts reported a 7.8% decrease in season-to-date total skier visits compared to last year. The company anticipates finishing the year at or around the low end of its resort reported EBITDA guidance range, which was previously issued on March 11, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 12:08 pm

CHRO

ERAS

HLTH

INVO

LIFW

NXL

In Friday's pre-market session, several healthcare stocks showed significant movement. Chromocell Therapeutics, Kineta, Portage Biotech, Erasca, MSP Recovery, and Cue Health were among the gainers, with increases ranging from 12.25% to 21.6%. On the downside, Nexalin Technology, iSpecimen, INVO Bioscience, Intelligent Bio Solutions, Trevena, and PaxMedica experienced declines between 9.58% and 18.4%. Notably, MSP Recovery and INVO Bioscience had recent earnings reports influencing their stock movements.

Portfolio Pulse from Benzinga Insights

April 19, 2024 | 12:08 pm

BDRX

Biodexa Pharmaceuticals reported preliminary financial results for FY23, announcing revenues of £0.38 million.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 12:07 pm

LBAI

Lakeland Bancorp (NASDAQ:LBAI) reported Q1 earnings per share of $0.30, surpassing the $0.27 estimate, but its sales of $67.65M fell short of the $69.61M estimate, marking a 17.69% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 12:04 pm

AA

Alcoa Corp (NYSE:AA) has been analyzed by 5 financial analysts, showing a shift towards a more bearish stance in the last 30 days with an increase in bearish ratings and a decrease in bullish ratings. Despite this, the average 12-month price target for Alcoa has risen to $36.00, indicating a 10.43% increase from the previous target of $32.60. Analysts from firms including UBS, B. Riley Securities, Jefferies, BMO Capital, and B of A Securities have raised their price targets, reflecting adjustments to market conditions and company performance. Alcoa, a leading aluminum company, faces challenges such as a decline in revenue, below-average net margin, and a high debt-to-equity ratio, impacting its financial health.

Portfolio Pulse from Benzinga Insights

April 19, 2024 | 12:01 pm

PG

Procter & Gamble Co (NYSE:PG) reported a slight sales growth of 1% Y/Y in Q3 FY24 to $20.195 billion, missing estimates. Organic sales grew 3%, driven by higher pricing. Adjusted EPS of $1.52 beat estimates, with gross profit up 7% and operating income rising 5%. P&G raised its FY24 EPS growth outlook and plans to return over $9 billion to shareholders through dividends and share repurchases. Shares fell 1.30% in premarket trading.

Portfolio Pulse from Shivani Kumaresan

April 19, 2024 | 11:59 am

DRI

KTB

TPR

Wall Street's most accurate analysts recommend three high-dividend yielding consumer stocks: Darden Restaurants, Inc. (DRI), Tapestry, Inc. (TPR), and Kontoor Brands, Inc. (KTB). DRI has mixed Q3 results, TPR faces a potential FTC lawsuit against its takeover of Capri, and KTB plans to release Q1 2024 financial results soon. Analysts have provided updated ratings and price targets for these stocks.

Portfolio Pulse from Avi Kapoor

April 19, 2024 | 11:59 am